Lucid Diagnostics Inc. (NASDAQ:LUCD) Given Average Recommendation of “Moderate Buy” by Brokerages

Lucid Diagnostics Inc. (NASDAQ:LUCD) has been assigned a consensus recommendation of “Moderate Buy” from the five research firms that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating and four have given a buy rating to the company. The average 1 year price target among analysts that have covered the stock in the last year is $3.8750.

Several research firms have commented on LUCD. BTIG Research boosted their target price on Lucid Diagnostics from $2.00 to $2.50 and gave the company a “buy” rating in a research note on Friday, September 5th. Ascendiant Capital Markets raised their target price on shares of Lucid Diagnostics from $7.75 to $8.00 and gave the company a “buy” rating in a research report on Monday, October 6th. Needham & Company LLC reissued a “buy” rating and set a $3.00 price target on shares of Lucid Diagnostics in a research report on Thursday, November 13th. Wall Street Zen downgraded shares of Lucid Diagnostics from a “hold” rating to a “sell” rating in a research note on Saturday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lucid Diagnostics in a research report on Wednesday, November 5th.

Institutional Trading of Lucid Diagnostics

Several institutional investors and hedge funds have recently bought and sold shares of LUCD. Bank of America Corp DE grew its stake in Lucid Diagnostics by 41.5% in the 3rd quarter. Bank of America Corp DE now owns 40,663 shares of the company’s stock valued at $41,000 after buying an additional 11,917 shares during the last quarter. Berkshire Asset Management LLC PA bought a new stake in Lucid Diagnostics during the first quarter worth about $30,000. Goldman Sachs Group Inc. boosted its position in shares of Lucid Diagnostics by 35.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 86,302 shares of the company’s stock worth $129,000 after acquiring an additional 22,727 shares in the last quarter. Northwestern Mutual Wealth Management Co. bought a new position in Lucid Diagnostics in the first quarter valued at approximately $37,000. Finally, Quadrature Capital Ltd bought a new position in Lucid Diagnostics in the second quarter valued at approximately $29,000. Institutional investors own 74.01% of the company’s stock.

Lucid Diagnostics Trading Down 1.9%

LUCD stock opened at $1.05 on Wednesday. The stock has a 50-day moving average price of $1.12 and a two-hundred day moving average price of $1.16. The stock has a market cap of $144.56 million, a PE ratio of -1.01 and a beta of 1.22. Lucid Diagnostics has a 1 year low of $0.75 and a 1 year high of $1.80.

Lucid Diagnostics (NASDAQ:LUCD) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.04). The firm had revenue of $1.21 million during the quarter, compared to the consensus estimate of $1.35 million. On average, analysts forecast that Lucid Diagnostics will post -0.84 earnings per share for the current fiscal year.

About Lucid Diagnostics

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.